Deep Brain Stimulation for the Treatment of Alzheimer's Disease

Status Completed

Clinical Trial Summary

The purpose of this clinical study is to investigate the safety and efficacy of deep brain stimulation (DBS)as a treatment option for patients with cognitive, behavioral, and functional disability of Alzheimer's disease.

Clinical Trial Description

Open label pilot study

- Expected direct benefit on the modulation of neuronal networks.

- Expected indirect benefit via potential enhancements of memory, executive functions, cognition behavioral control, and functional abilities.

Up to 10 subjects will be implanted with bilateral DBS systems, participants are expected to be on study for about 23 months.

- Develop a multidisciplinary clinical research protocol to evaluate the efficacy of ventral striatum, nucleus accumbens, and internal capsule for the amelioration of disability caused by Alzheimer's Disease.

- Enroll up to 10 patients into an open label study to evaluate the safety and efficacy of DBS for Alzheimer's Disease patients with mild to moderate disability.

- Determine an initial DBS titration and stimulation settings protocol for use in subsequent controlled trials.

- Evaluate the outcomes of this study based on clinical, laboratory, biomarker, imaging, cognitive, behavioral, and functional assessments.

- Determine what domains of cognitive, behavioral and functioning impairment show the greatest response to DBS.

- Examine the potential benefit of stimulation combined with behavioral and rehabilitation interventions in comparison to stimulation alone.

- Evaluate the influence of DBS on physiological and functional changes in cortical and subcortical networks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01559220
Study type	Interventional
Source	Ohio State University
Contact
Status	Completed
Phase	N/A
Start date	March 2012
Completion date	January 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05040048` - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn	`NCT03316898` - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease	Phase 1
Withdrawn	`NCT02860065` - CPC-201 Alzheimer's Disease Type Dementia: PET Study	Phase 2
Completed	`NCT01315639` - New Biomarker for Alzheimer's Disease Diagnostic	N/A
Not yet recruiting	`NCT03740178` - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)	Phase 1
Recruiting	`NCT05607615` - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease	Phase 2
Terminated	`NCT03307993` - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease	Phase 1
Recruiting	`NCT02912936` - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease	N/A
Active, not recruiting	`NCT02899091` - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease	Phase 1/Phase 2
Completed	`NCT02907567` - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease	Phase 1/Phase 2
Not yet recruiting	`NCT02868905` - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women	N/A
Completed	`NCT02580305` - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study	Phase 2
Completed	`NCT02516046` - 18F-AV-1451 Autopsy Study	Phase 3
Terminated	`NCT02521558` - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease	N/A
Recruiting	`NCT02247180` - Cognitive Rehabilitation in Alzheimer`s Disease	N/A
Completed	`NCT02260167` - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol	N/A
Completed	`NCT02256306` - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study	N/A
Terminated	`NCT02220738` - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors	Phase 1
Completed	`NCT02317523` - Alzheimer's Caregiver Coping: Mental and Physical Health	N/A
Completed	`NCT01920672` - Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD	N/A